Beam, Inc. (BEAM) reported Q3 EPS of ($1.56), $0.28 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $15.8 million versus the consensus estimate of...
Investing.com - Beam reported on Monday third quarter earnings that missed analysts' forecasts and revenue that topped expectations. Beam announced earnings per share of $-1.56...
Equal-weight ETFs invest equally between all holdings Inherently value-based Can mitigate risk as diversifies based on value Wall Street is enjoying a positive week, thanks to...
The sell-off in PFE Stock After Earnings Is Based On Quick Trigger Fingers Pfizer (NYSE:PFE) stock is dropping in mid-day trading after the company delivered a mixed earnings...
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children’s Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
|Average||80.08 (+83.12% Upside)|
|No. of Analysts||13|